『Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial』(JAMA Oncol 2021, published Jan…